Abivax S.A.

Abivax S.A. (ABVX) priced its initial public offering on Oct 23, 2023 at $11.60 per ADS, within its $11.60–$13.00 range, raising $235.8M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $729.3M. Morgan Stanley was lead-left underwriter, joined by Leerink Partners and LifeSci Capital. Dechert and Cooley advised the company and Latham & Watkins advised the underwriters.

Abivax S.A. is a clinical-stage biotechnology company developing therapeutics that modulate the immune response in chronic inflammatory diseases. Its lead candidate, obefazimod, is in Phase 3 trials for ulcerative colitis, and a Phase 2a trial is planned in Crohn's disease.

Status

IPO

Ticker

ABVX

Exchange

Nasdaq Global Market

Priced

Oct 23, 2023

IPO price

$11.60 per ADS

Price range

$11.60–$13.00

Raised

$235.8M

Market cap at IPO price

$729.3M

First filed

Sep 29, 2023

Underwriters

Morgan Stanley, Leerink Partners and LifeSci Capital

Company counsel

Dechert and Cooley

Underwriters' counsel

Latham & Watkins

Sector

Biotech & pharma

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.